<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

Press Releases

Our latest announcements

Data Published In AACR Journal Suggest Biodesix® Test in Development May Identify Melanoma Patients Who Could Benefit from Checkpoint Inhibitors

Findings in the AACR Journal on melanoma patient outcomes after anti PD1 therapy; a serum protein signature predicted survival.

Biodesix Leaders Share Commercial and Pipeline Updates at Annual qPCR and dPCR Congress

Biodesix leaders shared commercial and pipeline updates at the annual qPCR and dPCR Congress

Biodesix Announces New Data Demonstrating Analytic Validity of Automated RNA Extraction from Plasma with the GeneStrat® Test

Biodesix announces new data, presented at AMP2017, supporting the analytic validity of automated RNA extraction with the GeneStrat test

Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In Patients

Biodesix is making an oral presentation at SITC regarding a testing methodology that may identify primary immunotherapy resistance in patients

Biodesix Blood-Based Diagnostic Testing Approach To PD-L1 Detection Shows Concordance with Immunohistochemistry

Blood-based diagnostic approach to PD-L1 testing that shows concordance with immunohistochemistry; new data presented at EORTC

Biodesix To Present Data at SITC Annual Meeting

Biodesix will present posters and an oral presentation of data at SITC 2017 Annual Meeting.

2018 Preliminary Private Payor Rate-Based Payment Amounts Released for Clinical Diagnostic Laboratory Tests; Biodesix Commends CMS for Committing to On-Time PAMA Implementation

Biodesix commended the Centers for Medicare & Medicaid Services (CMS) for publishing preliminary 2018 rates for clinical diagnostic laboratory tests.

Study Published In Managed Care Regarding Prognostic and Cancer-Care Planning Value of Biodesix’s VeriStrat® Proteomic Test

A recent study published in the peer-reviewed journal Managed Care affirms VeriStrat; demonstrates the value of the VeriStrat lung cancer test

Interim Results from Biodesix® Study Indicate That VeriStrat Testing Impacts Treatment Decisions Across All Stages of Non-Small Cell Lung Cancer

Interim study results: Veristrat testing impacts lung cancer treatment in all stages; early stage patients get significantly different treatments after test

Biodesix Presents Cell-free DNA Process Optimization for Liquid Biopsy Test

Biodesix is presenting two talks on DNA process optimization at the Cancer Genomics Consortium